

Information for Pharmacists

**Claims Submission Procedure –
Lomustine 10mg and 40mg Capsules**

Effective November 30 ,2025

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

****Pharmacies do NOT receive drug interaction information when submitting claims using PINs. Please review all claims carefully prior to submitting****

- There is variable supply of Canadian labelled lomustine and it is being discontinued by the sole manufacturer. The following products will be discontinued:
 - Lomustine 10mg capsules (DIN: 00360430)
 - Lomustine 40mg capsules (DIN: 00360422)
- Due to this discontinuation, Manitoba is outlining the following product selection tree. This selection tree is to encourage pharmacy providers to use existing commercial supply while outlining an alternative option if supply is unavailable:
 - Canadian labelled product should be dispensed if the pharmacy has inventory on hand or can obtain product through normal distribution channels;
 - The pharmacy vendor may obtain Canadian labelled product from another provider (e.g., another member within the same chain);
 - If Canadian labelled product cannot be obtained, then foreign-labeled lomustine should be dispensed.
- The following PINs should be used when submitting claims for foreign-labelled lomustine 100 mg capsules:
 - **US-labelled lomustine 10mg** PIN: 00912138
 - **UK-labelled lomustine 40mg** PIN: 00912137

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:

<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to NIBDrugShortages@gov.mb.ca